While Navigating Risks, WuXi To Benefit from Global Outsourcing
This article was originally published in PharmAsia News
Executive Summary
BEIJING - WuXi PharmaTech is positioning itself to ride the rising tides of global pharmaceutical outsourcing to strengthen its role as China's largest contract research organization, according to a WuXi executive and an independent analyst
You may also be interested in...
Patheon Looks To Establish Stronger Ties with Japanese Pharmas
TOKYO - Toronto-based drug maker and developer Patheon created subsidiary Patheon K.K. in Tokyo this month in hopes of securing stronger ties with Japanese pharmaceutical companies
PharmAsia News Notable Notes: WuXi Confronts Chinese Macro Challenges
WuXi Pharma has systems in place to soften the impact of cost inflation issues expected to impact the Chinese pharma industry, according to Oppenheimer analyst Charles Rhyee
Insider Analysis From Jones Day: New Patent Approach Is Needed For Pharmaceutical Research In China
By Steven X. Cui, Ph.D., Jones Day, Beijing, and Tony Chen, Jones Day, Shanghai